CD33 and cancer: Kinetic assessments of DARIC33-induced cancer cell cytotoxicity showed rapid and complete rapamycin-dependent cancer cell killing only when the target antigen CD33 was expressed in cancer cells (Supplemental Figure 7, A and B).